Does the media favor AKTS or IRD?

In the previous week, Opus Genetics had 7 more articles in the media than Aktis Oncology. MarketBeat recorded 10 mentions for Opus Genetics and 3 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.26 beat Opus Genetics' score of 0.12 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IRD or MNKD?

MannKind has higher revenue and earnings than Opus Genetics. MannKind is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 21.67 -$49.59M -$1.35 N/A MannKind $348.97M 3.67 $5.86M -$0.13 N/A

Is IRD or MNKD more profitable?

MannKind has a net margin of -11.08% compared to Opus Genetics' net margin of -1,091.82%. MannKind's return on equity of -11.21% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% MannKind -11.08% -11.21% -6.31%

Does the media refer more to IRD or MNKD?

In the previous week, MannKind had 8 more articles in the media than Opus Genetics. MarketBeat recorded 18 mentions for MannKind and 10 mentions for Opus Genetics. MannKind's average media sentiment score of 0.30 beat Opus Genetics' score of 0.12 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MannKind 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, IRD or VOR?

Vor Biopharma has lower revenue, but higher earnings than Opus Genetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 21.67 -$49.59M -$1.35 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media favor IRD or VOR?

In the previous week, Opus Genetics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Opus Genetics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.45 beat Opus Genetics' score of 0.12 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vor Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ALVO or IRD?

Alvotech has higher revenue and earnings than Opus Genetics. Alvotech is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $588.90M 1.93 $27.92M -$0.25 N/A Opus Genetics $14.20M 21.67 -$49.59M -$1.35 N/A

Is ALVO or IRD more profitable?

Alvotech has a net margin of -14.36% compared to Opus Genetics' net margin of -1,091.82%. Alvotech's return on equity of -11.92% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Alvotech -14.36% -11.92% -7.59% Opus Genetics -1,091.82% -338.88% -150.13%

Does the media refer more to ALVO or IRD?

In the previous week, Opus Genetics had 8 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Opus Genetics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.16 beat Opus Genetics' score of 0.12 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IRD or WVE?

In the previous week, WAVE Life Sciences had 9 more articles in the media than Opus Genetics. MarketBeat recorded 19 mentions for WAVE Life Sciences and 10 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.12 beat WAVE Life Sciences' score of -0.06 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral WAVE Life Sciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Opus Genetics (IRD) Competitors

$3.73 +0.07 (+1.80%)

As of 11:07 AM Eastern

Compare

IRD vs. AKTS, MNKD, VOR, ALVO, and WVE

Should you buy Opus Genetics stock or one of its competitors? MarketBeat compares Opus Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Opus Genetics include Aktis Oncology (AKTS), MannKind (MNKD), Vor Biopharma (VOR), Alvotech (ALVO), and WAVE Life Sciences (WVE). These companies are all part of the "biotechnology" industry.

How does Opus Genetics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Opus Genetics has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	204.11	-$63.73M	-$0.38	N/A
Opus Genetics	$14.20M	21.67	-$49.59M	-$1.35	N/A

Aktis Oncology presently has a consensus price target of $34.60, indicating a potential upside of 39.26%. Opus Genetics has a consensus price target of $10.69, indicating a potential upside of 186.96%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Opus Genetics had 7 more articles in the media than Aktis Oncology. MarketBeat recorded 10 mentions for Opus Genetics and 3 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.26 beat Opus Genetics' score of 0.12 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aktis Oncology has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Aktis Oncology's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Summary

Aktis Oncology beats Opus Genetics on 8 of the 15 factors compared between the two stocks.

How does Opus Genetics compare to MannKind?

Opus Genetics (NASDAQ:IRD) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, MannKind had 8 more articles in the media than Opus Genetics. MarketBeat recorded 18 mentions for MannKind and 10 mentions for Opus Genetics. MannKind's average media sentiment score of 0.30 beat Opus Genetics' score of 0.12 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Opus Genetics presently has a consensus target price of $10.69, indicating a potential upside of 186.96%. MannKind has a consensus target price of $9.22, indicating a potential upside of 131.34%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has higher revenue and earnings than Opus Genetics. MannKind is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.67	-$49.59M	-$1.35	N/A
MannKind	$348.97M	3.67	$5.86M	-$0.13	N/A

MannKind has a net margin of -11.08% compared to Opus Genetics' net margin of -1,091.82%. MannKind's return on equity of -11.21% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
MannKind	-11.08%	-11.21%	-6.31%

Opus Genetics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, MannKind has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

MannKind beats Opus Genetics on 10 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Vor Biopharma?

Opus Genetics (NASDAQ:IRD) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Opus Genetics currently has a consensus target price of $10.69, indicating a potential upside of 186.96%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 77.44%. Given Opus Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Opus Genetics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Opus Genetics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

In the previous week, Opus Genetics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Opus Genetics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.45 beat Opus Genetics' score of 0.12 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vor Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma has lower revenue, but higher earnings than Opus Genetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.67	-$49.59M	-$1.35	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Vor Biopharma's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Opus Genetics on 7 of the 13 factors compared between the two stocks.

How does Opus Genetics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Alvotech has higher revenue and earnings than Opus Genetics. Alvotech is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.93	$27.92M	-$0.25	N/A
Opus Genetics	$14.20M	21.67	-$49.59M	-$1.35	N/A

In the previous week, Opus Genetics had 8 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Opus Genetics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.16 beat Opus Genetics' score of 0.12 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alvotech has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Alvotech has a net margin of -14.36% compared to Opus Genetics' net margin of -1,091.82%. Alvotech's return on equity of -11.92% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Alvotech currently has a consensus price target of $7.60, indicating a potential upside of 101.32%. Opus Genetics has a consensus price target of $10.69, indicating a potential upside of 186.96%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Opus Genetics beats Alvotech on 10 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to WAVE Life Sciences?

Opus Genetics (NASDAQ:IRD) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

WAVE Life Sciences has a net margin of -309.73% compared to Opus Genetics' net margin of -1,091.82%. WAVE Life Sciences' return on equity of -50.36% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Opus Genetics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.67	-$49.59M	-$1.35	N/A
WAVE Life Sciences	$42.73M	28.34	-$204.38M	-$1.09	N/A

In the previous week, WAVE Life Sciences had 9 more articles in the media than Opus Genetics. MarketBeat recorded 19 mentions for WAVE Life Sciences and 10 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.12 beat WAVE Life Sciences' score of -0.06 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

Opus Genetics presently has a consensus price target of $10.69, suggesting a potential upside of 186.96%. WAVE Life Sciences has a consensus price target of $22.53, suggesting a potential upside of 266.63%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

WAVE Life Sciences beats Opus Genetics on 11 of the 16 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$305.92M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.74	9.06	269.91	24.87
Price / Sales	21.67	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	16.94	17.97	11.40	6.45
Net Income	-$49.59M	-$13.25M	$3.45B	$347.50M
7 Day Performance	2.36%	5.58%	3.66%	3.77%
1 Month Performance	-4.95%	-1.60%	-0.49%	-0.40%
1 Year Performance	248.22%	61.32%	77.51%	23.55%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	2.7028 of 5 stars	$3.73 +1.8%	$10.69 +187.0%	+242.1%	$305.92M	$14.20M	N/A	14	Earnings Report Analyst Forecast
AKTS Aktis Oncology	2.2193 of 5 stars	$22.84 +2.7%	$34.60 +51.5%	N/A	$1.19B	$6.50M	N/A	76
MNKD MannKind	2.6019 of 5 stars	$3.96 +4.2%	$9.34 +136.0%	+16.8%	$1.17B	$348.97M	N/A	400	Analyst Downgrade
VOR Vor Biopharma	2.7914 of 5 stars	$22.25 +3.9%	$42.25 +89.9%	-42.8%	$1.16B	N/A	N/A	140	News Coverage Gap Down
ALVO Alvotech	3.6103 of 5 stars	$3.84 +1.3%	$7.60 +97.9%	-55.0%	$1.14B	$588.90M	N/A	1,460	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. AKTS, MNKD, VOR, ALVO, and WVE

How does Opus Genetics compare to Aktis Oncology?

Summary

How does Opus Genetics compare to MannKind?

Summary

How does Opus Genetics compare to Vor Biopharma?

Summary

How does Opus Genetics compare to Alvotech?

Summary

How does Opus Genetics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. AKTS, MNKD, VOR, ALVO, and WVE

How does Opus Genetics compare to Aktis Oncology?

Do institutionals & insiders believe in AKTS or IRD?

Which has preferable valuation & earnings, AKTS or IRD?

Do analysts prefer AKTS or IRD?

Does the media favor AKTS or IRD?

Is AKTS or IRD more profitable?

Summary

How does Opus Genetics compare to MannKind?

Does the media refer more to IRD or MNKD?

Do analysts prefer IRD or MNKD?

Which has higher earnings and valuation, IRD or MNKD?

Is IRD or MNKD more profitable?

Which has more volatility and risk, IRD or MNKD?

Do institutionals and insiders believe in IRD or MNKD?

Summary

How does Opus Genetics compare to Vor Biopharma?

Do institutionals and insiders believe in IRD or VOR?

Do analysts prefer IRD or VOR?

Which has more risk & volatility, IRD or VOR?

Does the media favor IRD or VOR?

Which has higher valuation and earnings, IRD or VOR?

Is IRD or VOR more profitable?

Summary

How does Opus Genetics compare to Alvotech?

Which has stronger valuation and earnings, ALVO or IRD?

Does the media refer more to ALVO or IRD?

Do institutionals and insiders believe in ALVO or IRD?

Which has more volatility and risk, ALVO or IRD?

Is ALVO or IRD more profitable?

Do analysts rate ALVO or IRD?

Summary

How does Opus Genetics compare to WAVE Life Sciences?

Do institutionals and insiders have more ownership in IRD or WVE?

Is IRD or WVE more profitable?

Which has stronger valuation and earnings, IRD or WVE?

Does the media favor IRD or WVE?

Which has more volatility & risk, IRD or WVE?

Do analysts rate IRD or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools